AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer

AstraZeneca (AZN.L) said its blockbuster cancer drug Imfinzi combined with chemotherapy has been approved by the U.S. as treatment for adult patients with primary, advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).